GMPS

Across TCGA pan-cancer cohorts, GMPS Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated GMPS data layer compared with 26 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher GMPS Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GMPS expression acts as an unfavorable survival marker, although some lineages such as MESO show a favorable association.

BRCA, LUAD, and LIHC are the cancer types where GMPS Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.289	0.925	<.001	36	view →
LUAD	OS	Median	II,III,IV	0.083	0.709	<.001	24	view →
LIHC	DFS	Median	All	0.165	0.546	.006	12	view →
HNSC	OS	Median	II,III,IV	0.196	0.710	.023	9	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
MESO	DFS	Median	All	1.000	0.179	.041	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

GMPS–BRCA (OS)

Open the BRCA breakdown →